| Followers | 54 |
| Posts | 6684 |
| Boards Moderated | 0 |
| Alias Born | 01/11/2017 |
Tuesday, August 10, 2021 10:01:17 AM
Thanks for sharing. I have no connection to Culper and went and read to the first link in its entirety. I would challenge anyone to read it and come back with a fact-based rebuttal to any of the assertions made. Sadly, they have been SPOT-ON and they use Nader's own assertions and promises.
Revenue promised years ago! debunked
BLA Approval years ago! debunked
Pestell fired for cause! debunked
Meeting and partnerships imminent! debunked
No dilution! Laughably debunked
Stock Price projections: Laughably off base
Seriously, while I love the Queen meme and the lyrics, it doesn't paint a picture of the reality.
Sub $1.41 price
No approvals
No revenue
Funding almost out if the Fife shelf isn't allowed
Shareholder lawsuits that cost MILLIONS of dollars
Arbitration loss for lying about firing Pestell
CD10 and CD12 FAILED! The 82% is a subset of a subset. Cytodyn's SEC filings say it failed! They didn't meet the endpoints. PERIOD, hard stop.
As a value investor, I'm looking for which portions of that report are not true.
Culper readily outlines it's their OPINION based on the science, trials, assertions and failures. They're totally in the clear.
Now, a CEO spewing triple-digit stock projections while selling $10+ million in stock and the CFO selling $5-6M in stock during the runup might get the SEC and DOJ's attention...oh wait! Subpoena's have been issued to a two-time felon who declared personally bankruptcy twice. Is that the moral fiber and fiscal responsibility that a mechanical engineer should possess to run a bio company?
I look forward to your response. I find them valuable.
Grip
Revenue promised years ago! debunked
BLA Approval years ago! debunked
Pestell fired for cause! debunked
Meeting and partnerships imminent! debunked
No dilution! Laughably debunked
Stock Price projections: Laughably off base
Seriously, while I love the Queen meme and the lyrics, it doesn't paint a picture of the reality.
Sub $1.41 price
No approvals
No revenue
Funding almost out if the Fife shelf isn't allowed
Shareholder lawsuits that cost MILLIONS of dollars
Arbitration loss for lying about firing Pestell
CD10 and CD12 FAILED! The 82% is a subset of a subset. Cytodyn's SEC filings say it failed! They didn't meet the endpoints. PERIOD, hard stop.
As a value investor, I'm looking for which portions of that report are not true.
Culper readily outlines it's their OPINION based on the science, trials, assertions and failures. They're totally in the clear.
Now, a CEO spewing triple-digit stock projections while selling $10+ million in stock and the CFO selling $5-6M in stock during the runup might get the SEC and DOJ's attention...oh wait! Subpoena's have been issued to a two-time felon who declared personally bankruptcy twice. Is that the moral fiber and fiscal responsibility that a mechanical engineer should possess to run a bio company?
I look forward to your response. I find them valuable.
Grip
Recent CYDY News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 08:32:50 PM
- CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer • GlobeNewswire Inc. • 04/27/2026 12:30:00 PM
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
- CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer • GlobeNewswire Inc. • 01/27/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/09/2026 10:15:22 PM
